-+ 0.00%
-+ 0.00%
-+ 0.00%

aTyr Pharma expects FDA response by mid-September on efzofitimod Phase 3 sarcoidosis protocol

PUBT·09/01/2026 20:36:28
Listen to the news
aTyr Pharma expects FDA response by mid-September on efzofitimod Phase 3 sarcoidosis protocol
  • aTyr Pharma expects an FDA response by mid-September on its June protocol submission for a planned Phase 3 efzofitimod trial.
  • Regulatory feedback timing is a key gating item for launching the global pivotal study in pulmonary sarcoidosis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609011636PRIMZONEFULLFEED9819748) on September 01, 2026, and is solely responsible for the information contained therein.